Gene Silencing Method Based on DNA

Journal of Cell and Molecular Research

مقاله 2، دوره 15، شماره 1 - شماره پیاپی 29، دی 2023، صفحه 7-18   

نوع مقاله: Review / Mini-Review

شناسه دیجیتال (DOI): 10.22067/jcmr.2023.84052.1077

نویسندگان

Mitra Riasi¹؛ Elnaz Karbaschian¹؛ Ali Javadmanesh^{* 1، 2}

¹Department of Animal Science, Faculty of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran

²Industrial Biotechnology Research Group, Research Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran

چکیده

DNA-based approaches can now be utilized as low-risk methods to change gene expression. It appears that this approach has the ability to partially replace RNA-based approaches for altering gene expression, which in the majority of cases leads to immunological responses in patients. When utilized as a technique to silence target gene expression, DNA interference (DNAi) is a single-stranded DNA created to complement the upstream region of a gene. This DNAi molecule is stabilized using a variety of chemical changes, including phosphorothioates, methylphosphonate setC, etc. Several studies of the efficient application of DNA-based methods both in eukaryotic cell lines and the therapy of various disorders, such as Duchenne muscular dystrophy, cancer, etc., have been mentioned. Understanding the DNAi process, its transfer carriers, stabilization techniques, and their limitations is crucial for advancing these applications and predicting the future of DNAi both in basic science and the treatment of disorders brought on by abnormal gene expression. The main purpose of this review is introducing benefits of using DNAi in gene silencing. this review has discussed about different applications of DNAi in drug discovery and treatment, criteria of designing DNAi, possible modifications, introducing different types of carriers and limitations of DNAi administration.

کلیدواژه‌ها

DNAi؛ gene silencing؛ phosphorothioates؛ gene therapy

مراجع

Aartsma-Rus A., De Winter C. L., Janson A. A., Kaman W. E., Van Ommen G.J. B., Den Dunnen J. T., et al. (2005) Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Journal Oligonucleotides 15(4):284-197.

Aartsma-Rus A., Singh K. H., Fokkema I. F., Ginjaar I. B., van Ommen G. J., den Dunnen J. T., et al. (2010) Therapeutic exon skipping for dysferlinopathies? European Journal of Human Genetics, 18(8):889-894.

Anwar S. and Yokota T. (2020) Golodirsen for Duchenne muscular dystrophy. Journal Drugs of Today 56(8):491-504.

Arthur G. K. and Cruse G. (2018) Exon skipping of FcεRIβ for allergic diseases. J Exon Skipping Inclusion Therapies: Methods Protocols 503-518 pp.

Arzumanov A., Stetsenko D. A., Malakhov A. D., Reichelt S., Sørensen M. D., Babu B. R., et al. (2003) A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2′-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), α-L-LNA, or 2′-thio-LNA residues. Journal of Oligonucleotides 13(6):435-453.

Bennett C. F. and Swayze E. E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. J Annual Review of Pharmacology Toxicology 50:259-293.

Blenke E. O., Evers M. J., Baumann V., Winkler J., Storm G. and Mastrobattista E. J. (2018) Critical evaluation of quantification methods for oligonucleotides formulated in lipid nanoparticles. J International Journal of Pharmaceutics 548(2):793-802.

Buck A. C., Shen C., Schirrmeister H., Schmid-Kotsas A., Munzert G., Guhlmann, A., et al. (2002) Liposomal delivery of antisense oligonucleotides for efficient downregulation of Bcl-2 and induction of apoptosis. Journal of Cancer Biotherapy Radiopharmaceuticals 17(3):281-289.

Cohen P. T. and Cohen P. (1989) Discovery of a protein phosphatase activity encoded in the genome of bacteriophage λ. Probable identity with open reading frame 221. Biochemical Journal 260(3):931-934.

Davids M. S., and Letai A. (2012) Targeting the B-cell lymphoma/leukemia 2 family in cancer. Journal of Clinical Oncology 30(25):3127.

De Mesmaeker A., Altmann K.H., Waldner A. and Wendeborn S. (1995) Backbone modifications in oligonucleotides and peptide nucleic acid systems. Journal of Current Opinion in Structural Biology 5(3):343-355.

Dean N. M., and McKay R. (1994) Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Journal of Proceedings of the National Academy of Sciences 91(24):11762-11766.

Deleavey G. F. and Damha M. J. (2012) Designing chemically modified oligonucleotides for targeted gene silencing. Journal of Chemistry Biology 19(8):937-954.

Dewanjee M. K. (1993) RADIOLABELED ANTISENSE PROBES-DIAGNOSIS AND THERAPY. Journal of Diagnostic Oncology 3(4):189-208.

Dominski Z. and Kole R. (1993) Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Journal of Proceedings of the National Academy of Sciences 90(18):8673-8677.

Dzierlega K. and Yokota T. (2020) Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy. Journal of Gene Therapy 27(9):407-416.

Ebrahim A. S., Kandouz M., Emara N., Sugalski A. B., Lipovich L. and Al-Katib A. M. (2017). Unintended target effect of anti-BCL-2 DNAi. Journal of Cancer Management Research 427-432 pp.

Eckstein F. (2000) Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Journal of Antisense Nucleic Acid Drug Development 10(2):117-121.

Elayadi A. N., Braasch D. A. and Corey D. R. (2002) Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Journal of Biochemistry 41(31):9973-9981.

Elmén J., Zhang H.Y., Zuber B., Ljungberg K., Wahren B., Wahlestedt C., et al. (2004) Locked nucleic acid containing antisense oligonucleotides enhance inhibition of HIV-1 genome dimerization and inhibit virus replication. Journal of FEBS letters 578(3):285-290.

Finke R. (2016) The consequences of religious competition: Supply-side explanations for religious change. In Rational choice theory and religion (pp. 46-65): Routledge.

Fire A., Xu S., Montgomery M. K., Kostas S. A., Driver S. E. and Mello C. C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Journal of Nature 391(6669):806-811.

Fluiter K., ten Asbroek A. L., van Groenigen M., Nooij M., Aalders M. C. and Baas F. (2002) Tumor genotype-specific growth inhibition in vivo by antisense oligonucleotides against a polymorphic site of the large subunit of human RNA polymerase II. Journal of Cancer Research 62(7):2024-2028.

Graham M. J., Crooke S. T., Monteith D. K., Cooper S. R., Lemonidis K. M., Stecker K. K., et al. (1998) In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration.  Journal of Pharmacology Experimental Therapeutics 286(1):447-458.

Hansen J. B., Westergaard M., Albaek Thrue C., Giwercman B. and Oerum H. (2003) Antisense knockdown of PKC-α using LNA-oligos. Journal of Nucleosides, Nucleotides Nucleic Acids 22(5-8):1607-1609.

Harb W., Lakhani N. J., Messmann R., Klencke B. and Al-Katib A. M. (2021) A phase 2 study of PNT2258 for treatment of relapsed or refractory B-cell malignancies. Journal of Clinical Lymphoma Myeloma Leukemia 21(12):823-830.

Kawai-Toyooka H., Kuramoto C., Orui K., Motoyama K., Kikuchi K., Kanegae T., et al. (2004) DNA interference: a simple and efficient gene-silencing system for high-throughput functional analysis in the fern Adiantum. Journal of Plant Cell Physiology 45(11):1648-1657.

Knudsen J. B., Liu L., Bank Kodal A. L., Madsen M., Li Q., Song J., et al. (2015) Routing of individual polymers in designed patterns. Journal of Nature Nanotechnology 10(10):892-898.

Koed Doktor T., Schroeder L. D., Vested A., Palmfeldt J., Andersen H. S., Gregersen N., et al. (2011) SMN2 exon 7 splicing is inhibited by binding of hnRNP A1 to a common ESS motif that spans the 3′ splice site. Journal of Human Mutation 32(2):220-230.

Kontturi L.-S., Van Den Dikkenberg J., Urtti A., Hennink W. E. and Mastrobattista E. (2019) Light-triggered cellular delivery of oligonucleotides. Journal of Pharmaceutics 11(2):90.

Lee J.Y., Lee B.-S., Shin D.J., Woo Park K., Shin Y.A., Joong Kim K., et al. (2013) A genome-wide association study of a coronary artery disease risk variant. Journal of Human Genetics 58(3):120126.

Lefebvre S., Bürglen L., Reboullet S., Clermont O., Burlet P., Viollet L., et al. (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Journal of Cell 80(1):155-165.

Lehto T., Ezzat K., Wood M. J. and Andaloussi S. E. (2016) Peptides for nucleic acid delivery. Journal of Advanced Drug Delivery Reviews 106:172-182.

Lei Mon S. S., Yoshioka K., Jia C., Kunieda T., Asami Y., Yoshida‐Tanaka., et al. (2020) Highly efficient gene silencing in mouse brain by overhanging‐duplex oligonucleotides via intraventricular route. Journal of FEBS letters 594(9):1413-1423.

Letsinger R. L., Singman C. N., Histand G. and Salunkhe M. (1988) Cationic oligonucleotides. Journal of the American Chemical Society 110(13):4470-4471.

Lim K. R. Q., Maruyama R. and Yokota T. (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Journal of Drug Design, Development Therapy 533-545 pp.

Manzur A. Y., Kuntzer T., Pike M. and Swan A. V. (2008) Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Journal of Cochrane Database of Systematic Reviews (1).

Marshall W. and Caruthers M. (1993) Phosphorodithioate DNA as a potential therapeutic drug. Journal of Science 259(5101):1564-1570.

Matsukura M., Shinozuka K., Zon G., Mitsuya H., Reitz M., Cohen J. S., et al. (1987) Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Journal of Proceedings of the National Academy of Sciences 84(21):7706-7710.

McManus M. T. and Sharp P. A. (2002) Gene silencing in mammals by small interfering RNAs. Journal of Nature Reviews Genetics 3(10):737-747.

Melki J., Abdelhak S., Sheth P., Bachelot M., Burlet P., Marcadet A., et al. (1990) Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. Journal of Nature 344(6268):767-768.

Miller P. S., Fang K. N., Kondo N. S. and Ts'o P. O. (1971) Syntheses and properties of adenine and thymine nucleoside alkyl phosphotriesters, the neutral analogs of dinucleoside monophosphates. Journal of the American Chemical Society 93(24):6657-6665.

Miller P. S., Yano J., Yano E., Carroll C., Jayaraman K. and Ts'o P. O. (1979) Nonionic nucleic acid analogs. Synthesis and characterization of dideoxyribonucleoside methylphosphonates. Journal of Biochemistry 18(23):5134-5143.

Moelling K., Abels S., Jendis J., Matskevich A. and Heinrich J. (2006) Silencing of HIV by hairpin-loop-structured DNA oligonucleotide. Journal of FEBS letters 580(14):3545-3550.

Muntoni F., Torelli S. and Ferlini A. (2003) Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Journal of The Lancet Neurology 2(12):731-740.

Ng C. L., Lee S. E., Lee J. K., Kim T. H., Jang W. S., Choi J. S., et al. (2016) Solubilization and formulation of chrysosplenol C in solid dispersion with hydrophilic carriers. International Journal of Pharmaceutics 512(1):314-321.

Odeh F., Nsairat H., Alshaer W., Ismail M. A., Esawi E., Qaqish B., et al. (2019) Aptamers chemistry: Chemical modifications and conjugation strategies. Journal of Molecules 25(1):3.

Omotezako T., Onuma T. A. and Nishida H. (2015) DNA interference: DNA-induced gene silencing in the appendicularian Oikopleura dioica. Journal of Proceedings of the Royal Society B: Biological Sciences 282(1807):20150435.

Palauqui J.C. and Balzergue, S. (1999) Activation of systemic acquired silencing by localised introduction of DNA. Journal of Current Biology 9(2):59-66.

Pao P. W., Wee K. B., Yee W. C. and DwiPramono Z. A. (2014) Dual masking of specific negative splicing regulatory elements resulted in maximal exon 7 inclusion of SMN2 gene. Journal of Molecular Therapy 22(4):854-861.

Payande H., Ghahramani Seno M. M. and Javadmanesh A. (2019) The inhibitory effect of myostatin-specific siRNA on the differentiation and growth of C2C12 cells. Paper presented at the The 3rd International & the 11th National Biotechnology Congress of Islamic Republic of Iran.

Payande H., Javadmanesh A. and Ghahremani Seno M. M. (2019) Inhibition of myostatin gene expression in C2C12 cells by RNAi and DNAi methods. Master Tesis. Ferdowsi University of Mashhad.

Prakash T. P., Mullick A. E., Lee R. G., Yu J., Yeh S. T., Low A., et al. (2019) Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle. Journal of Nucleic Acids Research, 47(12):6029-6044.

Psaras A. M., Chang K. T., Hao T. and Brooks T. A. (2021) Targeted Downregulation of MYC through G-quadruplex Stabilization by DNAi. Journal of Molecules 26(18):5542.

Purwaningsih E. H., and Schubert, R. (2010) The Preparation of Liposomes derived from Mixed Micelles of Lecithin added by Sodium Cholate, followed by Dialysing using Hemoflow High Flux F60S. Journal of Makara Journal of Health Research, 49-52 pp.

Riasi M. and Javadmanesh A. (2020) Limitations of DNA Interference in Targeted Drug Delivery. Paper presented at the International Congress on Biomedicine 2020.

Riasi M., Javadmanesh A. and Mozaffari Jovin S. (2022) Inhibition of myostatin gene expression in mouse by DNAi, RNAi and ddRNAi methods. Master Tesis. Ferdowsi University of Mashhad.

Riasi M., Mozaffari Jovin S. and Javadmanesh A. (2022) Inhibition of myostatin gene expression using siRNA in mice. Paper presented at the The 22nd National and 10th Intenational Congress on Biology.

Riasi M., Mozaffari Jovin S. and Javadmanesh A. (2023) The effect of modification of DNA interference on myostatin gene expression in mice. Journal of Genetics.

Rigo F., Hua Y., Krainer A. R. and Bennett C. F. (2012) Antisense-based therapy for the treatment of spinal muscular atrophy. In: The Rockefeller University Press.

Rodrigueza W. V., Woolliscroft M. J., Ebrahim A. S., Forgey  R., McGovren P. J., Endert G., et al. (2014) Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide. Journal of Cancer Chemotherapy Pharmacology 74:151-166.

Roshmi R., and Yokota T. (2019) Viltolarsen for the treatment of Duchenne muscular dystrophy. Journal of Drugs Today 55(10):627.

Rutherford G., Tanurdzic M., Hasebe M. and Banks J. A. (2004) A systemic gene silencing method suitable for high throughput, reverse genetic analyses of gene function in fern gametophytes. Journal of BMC Plant Biology 4(1) 1-10.

Saravani F. B., Tafvizi F. and Jaafari M. R. (2018) The Effect of Synthesis of Pegylated Nanoliposome Containing DNAi on Reduction of BCL-2 Gene Expression in DLCL2 Cell Line. Qom Univ Med Sci.

Sheikhnejad R., Ashrafi F., Talebi A., Mazaheri B., Moslemi F. and Nematbakhsh M. (2021) Bicelin (B-cell lymphoma 2 inhibitor) a Highly Safe DNA-based Anti-cancer Drug Showed No in vivo Cytopenia, Nephrotoxicity and/or Hepatotoxicity. Reasearch Square.

Shirley M. (2021) Casimersen: first approval. Journal of Drugs 81:875-879.

Singh N. K., Singh N. N., Androphy E. J. and Singh R. N. (2006) Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Journal of Molecular Cellular Biology 26(4):1333-1346.

Slijkerman R. W., Vaché C., Dona M., García-García G., Claustres M., Hetterschijt L., et al. (2016) Antisense oligonucleotide-based splice correction for USH2A-associated retinal degeneration caused by a frequent deep-intronic mutation. Journal of Molecular Therapy-Nucleic Acids 5.

Souleimanian N., Deleavey G. F., Soifer H., Wang S., Tiemann K., Damha M. J., et al. (2012) Antisense 2′-deoxy, 2′-fluoroarabino nucleic acid (2′ F-ANA) oligonucleotides: in vitro gymnotic silencers of gene expression whose potency is enhanced by fatty acids. Journal of Molecular Therapy-Nucleic Acids 1.

Spitali P. and Aartsma-Rus A. (2012) Splice modulating therapies for human disease. Journal of Cell, 148(6):1085-1088.

Sumner C. J. and Crawford T. O. (2018) Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. The Journal of Clinical Investigation 128(8):3219-3227.

Szabó Z., Hämäläinen J., Loikkanen I., Moilanen A. M., Hirvikoski P., Väisänen T., et al. (2010) Sorbitol dehydrogenase expression is regulated by androgens in the human prostate. Journal of Oncology Reports 23(5):1233-1239.

Taylor G. J., Bagby R. M. and Parker J. D. (1999) Disorders of affect regulation: Alexithymia in medical and psychiatric illness: Cambridge University Press.

Thaler D. S., Liu S. and Tombline G. (1996) Extending the chemistry that supports genetic information transfer in vivo: phosphorothioate DNA, phosphorothioate RNA, 2'-O-methyl RNA, and methylphosphonate DNA. J Proceedings of the National Academy of Science 93(3):1352-1356.

Tolcher A. W., Rodrigueza W. V., Rasco D. W., Patnaik A., Papadopoulos K. P., Amaya A., et al. (2014) A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Journal of Cancer Chemotherapy Pharmacology 73:363-371.

Touznik A., Lee J. J. and Yokota T. (2014) New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Journal of Expert Opinion on Biological Therapy 14(6):809-819.

Tsujimoto Y., Finger L. R., Yunis J., Nowell P. C. and Croce C. M. (1984) Cloning of the chromosome breakpoint of neoplastic B cells with the t (14; 18) chromosome translocation. Journal of Science, 226(4678):1097-1099.

Uhlmann E. and Peyman A. (1990) Antisense oligonucleotides: a new therapeutic principle. Journal of Chemical Reviews 90(4):543-584.

Urban E. and Noe C. R. (2003) Structural modifications of antisense oligonucleotides. Journal of Il Farmaco 58(3):243-258.

Van Den Bergen J., Wokke B., Janson A., Van Duinen S., Hulsker M., Ginjaar H., et al. (2014) Dystrophin levels and clinical severity in Becker muscular dystrophy patients. Journal of Neurology, Neurosurgery Psychiatry 85(7):747-753.

Varma R. S. (1993) Synthesis of oligonucleotide analogues with modified backbones. Journal of Synlett, 1993(09):621-637.

Voinnet O., Vain P., Angell S. and Baulcombe D. C. (1998) Systemic spread of sequence-specific transgene RNA degradation in plants is initiated by localized introduction of ectopic promoterless DNA. Journal of Cell 95(2):177-187.

Wang Y., Miao L., Satterlee A. and Huang L. (2015) Delivery of oligonucleotides with lipid nanoparticles. J Advanced Drug Delivery Reviews 87:68-80.

Węsierska‐Gądek J., Schloffer D., Kotala V. and Horky M. (2002) Escape of p53 protein from E6‐mediated degradation in HeLa cells after cisplatin therapy. J International Journal of Cancer 101(2):128-136.

Wilton S. D., Fall A. M., Harding P. L., McClorey G., Coleman C. and Fletcher S. (2007) Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Journal of Molecular Therapy 15(7):1288-1296.

Yonetani N., Ueda C., Akasaka T., Nishikori M., Uchiyama T. and Ohno H. (2001) Heterogeneous breakpoints on the immunoglobulin genes are involved in fusion with the 5′ region of BCL2 in B‐cell tumors. J Japanese Journal of Cancer Research 92(9):933-940.